Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

The study identified increased IL-24 expression in keratinocytes and fibroblasts exposed to particulate matter, contributing to skin aging by promoting conditions similar to age-related changes such as increased MMP1 expression and decreased type I collagen production.

This study found that the Hair660™ low-level light therapy device significantly improved hair density and was safe for men with androgenetic alopecia over 24 weeks.

This study found that applying a combination of pyridine‐2, 4‐dicarboxylic acid diethyl ester and resveratrol significantly increased hair density in Caucasian women after 1.5 months, potentially due to their synergistic effect on the HIF‐1α pathway.

This study found that the black bean-licorice-biotae folium extract may improve hair diameter, scalp moisture, and sebum secretion, although its effect on hair density was not significant.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

In this study on adult-onset, whole body Spry1/2/4 triple knockout mice, researchers observed endocrine abnormalities and no increased tumor incidence, despite similar food intake and motor function.

In this cross-sectional study, researchers found that those without a diabetic background had higher levels of secreted frizzled related protein-4, while family history of diabetes was strongly correlated with waist circumference, waist-to-height ratio, and insulin resistance but not significantly linked to protein-4 levels.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study reports that a patient with severe, treatment-resistant alopecia areata experienced sustained hair regrowth and emotional improvement over 24 months following individualized homeopathic treatment, suggesting homeopathy may be a viable therapeutic option when conventional treatments fail.

This study characterized the crystal structures and supramolecular architectures of new salts made from 2,4-diaminopyrimidine and different dicarboxylic acids, revealing subtle differences in crystal packing and hydrogen-bonding patterns, particularly influenced by sulfur atom interactions, through Hirshfeld analysis and enrichment ratios.

In this study, the synthesis and testing of new pyrroloquinoline derivatives identified compound 7p, which showed low micromolar cytotoxic activity against MCF-7 and HeLa cells, highlighting its potential for development into a potent anticancer agent.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study found that monoclonal antibodies can identify specific immunological characteristics of hair fibrous proteins, with some antibodies reacting only with hair proteins and others showing broader activity with skin and epithelial cells.

This study found that oral minoxidil 5 mg daily significantly improves hair growth in men with androgenetic alopecia, although common side effects include hypertrichosis and pedal edema.

In this randomized, double-blind, placebo-controlled trial, researchers found that a multi-targeted cosmetic formulation containing TrinogeniX™ significantly increased hair density and thickness in individuals with androgenetic alopecia without adverse effects, suggesting it as a potential safe and effective treatment option.

The congress was praised for its organization and educational value.

This study concluded that a regimen containing functional antioxidants and barrier-enhancing agents reduced hair shedding and increased perceived hair fullness in participants with self-perceived hair thinning over 24 weeks.

Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.

This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.